{"title": "COVID-19 - Merck.com", "author": null, "url": "https://www.merck.com/research/covid-19/", "hostname": "merck.com", "description": "Merck is committed to advancing research and development efforts for our investigational oral antiviral COVID-19 medicine and making a meaningful impact on the pandemic.", "sitename": "Merck.com", "date": "2023-06-05", "cleaned_text": "Our COVID-19 efforts As a company with a long legacy of research in vaccines and [infectious diseases](https://www.merck.com/research/infectious-diseases/), we've been committed to advancing an effective response to COVID-19 since it was first recognized. We've been focused on contributing our scientific expertise and experience to help address COVID-19. Our investigational oral antiviral COVID-19 medicine In collaboration with Ridgeback Biotherapeutics, we advanced our research and development efforts for our investigational oral antiviral COVID-19 medicine. We continue to make a meaningful impact with this important tool for physicians, patients and the health care system. We're working with health authorities to make our oral antiviral treatment available globally. Our commitment to access We have a long track record of making our medicines and vaccines accessible and affordable. Our comprehensive supply and access strategy has enabled timely and broad access to our investigational oral antiviral COVID-19 medicine to patients around the world, including in low- and middle-income countries. Our approach includes purchase and supply agreements with the governments of several countries worldwide. Additionally, we signed [voluntary license agreements](https://www.merck.com/news/amid-humanitarian-crisis-in-india-merck-announces-voluntary-licensing-agreements-with-five-indian-generics-manufacturers-to-accelerate-and-expand-global-access-to-molnupiravir-an-investigational-ora/) with multiple generic manufacturers and the [Medicines Patent Pool](https://www.merck.com/news/the-medicines-patent-pool-mpp-and-merck-enter-into-license-agreement-for-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-to-increase-broad-access-in-low-and-middle-income-countri/) to help make generic versions of our treatment option available to more than 100 low- and middle-income countries. We've also allocated up to 3 million courses of therapy to UNICEF for low- and middle-income countries. Through our licensing agreements with generics manufacturers and the Medicines Patent Pool, more than 5 million courses of generic therapy have been delivered to 22 low- and middle-income markets included in the licenses through December 2022. Clinical trials We continue our research efforts to study our oral antiviral medicine in other infectious diseases. Learn more about our research and [find a clinical trial](https://merckclinicaltrials.com/). Stepping up to combat COVID-19 as a company Throughout the COVID-19 pandemic, we've prioritized the health, safety and well-being of our employees and their families, and supported our health care providers and our communities, including through volunteer and donation efforts. Our work continues, and we'll further support efforts to fight COVID-19. COVID-19 Stories Our work in the fight against COVID-19 reaches across all corners of our company, our personal lives and our communities, where many of our medically trained employees have volunteered their time. [View our stories](https://www.merck.com/stories/) COVID-19 study participant: 'It's pretty amazing to say I was a part of that' A mother of two shares her experience volunteering in a clinical trial [Read more](https://www.merck.com/stories/covid-19-study-participant-shares-her-experience-volunteering-in-a-clinical-trial/) Addressing health equity in the age of COVID-19 In this Teal Talks episode, health care influencers Dr. Marcella Nunez-Smith and Dr. Aletha Maybank discuss how the pandemic has impacted health equity and disparities [Read more](https://www.merck.com/stories/addressing-health-equity-in-the-age-of-covid-19/) An oral history: Stepping up throughout the COVID-19 pandemic Scientists, leaders, global partners and more reflect on how we rose to the challenge and worked together, one moment at a time [Read more](https://www.merck.com/stories/an-oral-history-stepping-up-throughout-the-covid-19-pandemic/) 6 global trends critical to patients during the COVID-19 pandemic Expert panel of patient advocacy leaders on COVID-19, its impact on patients and moving forward [Read more](https://www.merck.com/stories/6-global-trends-critical-to-patients-during-the-covid-19-pandemic/) COVID-19 study participant: 'It's pretty amazing to say I was a part of that' A mother of two shares her experience volunteering in a clinical trial [Read more](https://www.merck.com/stories/covid-19-study-participant-shares-her-experience-volunteering-in-a-clinical-trial/) Addressing health equity in the age of COVID-19 In this Teal Talks episode, health care influencers Dr. Marcella Nunez-Smith and Dr. Aletha Maybank discuss how the pandemic has impacted health equity and disparities [Read more](https://www.merck.com/stories/addressing-health-equity-in-the-age-of-covid-19/) An oral history: Stepping up throughout the COVID-19 pandemic Scientists, leaders, global partners and more reflect on how we rose to the challenge and worked together, one moment at a time [Read more](https://www.merck.com/stories/an-oral-history-stepping-up-throughout-the-covid-19-pandemic/) 6 global trends critical to patients during the COVID-19 pandemic Expert panel of patient advocacy leaders on COVID-19, its impact on patients and moving "}